Positive Clinical Study Results for Cellmid's Hair Growth Product Using Novel FGF5 Inhibitor

21-Apr-2015 - Australia

Cellmid Limited has received strong positive results in all measured areas of its independently conducted, randomized, blinded and placebo controlled human clinical study of the évolis ONE formulation. The 32 patient study was conducted with Cellmid’s novel and proprietary FGF5 inhibitor formulation, évolis ONE, which is a fully optimised, GMP manufactured and market ready product.

Using Gravimetric Analysis1 évolis ONE has shown a statistically significant 80.2% reduction in hair loss over 112 days (16 weeks) with twice daily use. Hair differentiation (or anagen/telogen ratio, a measure of growing versus resting hair follicles) improved with an increase of 44.2% in growing follicles during the same period, as analysed by the Van Scott “hair pluck” method2.  Hair release and recovery (overall improvement in hair quality and volume) was quantified by PhotoGrammetrix™3 measurements and has shown an improvement by a statistically significant 143.3%.  

The trial was conducted by AMA Laboratories, INC. in New York, a leading independent CRO specialising in dermatological product testing. The efficacy study followed a 51 subject Repeat Insult Patch Test (RIPT) to assess safety by evaluating skin irritation and sensitisation. The safety study, also conducted by AMA Laboratories, resulted in a “zero adverse event” report.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...